Please use this identifier to cite or link to this item: http://hdl.handle.net/1822/62577

TitleLeukemia inhibitory factor: recent advances and implications in biotechnology
Author(s)Pinho, Vanessa
Fernandes, Mário
da Costa, André
Machado, Raul
Gomes, Andreia C.
KeywordsLIF
Multiple sclerosis
Cytokine
Astrocytes
Brain injury
Myelination
Stroke
Issue date2019
PublisherElsevier
JournalCytokine & Growth Factor Reviews
Abstract(s)Leukemia inhibitory factor (LIF) is a pleiotropic cytokine with several functions in health and disease ranging from inflammation to cancer. LIF is also a potential target and/or therapeutic agent for diseases such as multiple sclerosis, stroke and even psychological disorders, where the function of LIF as a neurotrophic factor has only recently been explored. In recent years, a limited number of LIF clinical trials have been completed, which partially explains the shortage of effective applications as a therapeutic agent. With the increasing interest from biotechnology companies producing recombinant LIF, this status quo will certainly change, and the potential impact of LIF in terms of disease diagnosis, treatment and management will be realized.
TypeArticle
Description"In Press, Journal Pre-proof"
URIhttp://hdl.handle.net/1822/62577
DOI10.1016/j.cytogfr.2019.11.005
ISSN1359-6101
e-ISSN1879-0305
Publisher versionhttps://www.sciencedirect.com/science/article/pii/S1359610119301145
Peer-Reviewedyes
AccessEmbargoed access (3 Years)
Appears in Collections:DBio - Artigos/Papers

Files in This Item:
File Description SizeFormat 
PrePrint_1-s2.0-S1359610119301145-main.pdf
  Until 2023-01-01
2,41 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID